Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NVA237 placebo-controlled phase 3 study in moderate-to-severe COPD
2009-013504-32Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing glycopyrronium bromide with placebo (2 arms). Primary endpoints: Trough FEV1 at week 12, FVC and 1 more. Started Aug 2009; status: completed.
02
Drugs
glycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2009-013504-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013504-32.